Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2019

View Archived Issues

Using promiscuity to identify high-commitment targets

Local vaccine can induce global remission

Design of EBNA1-specific inhibitors suppressing Epstein-Barr virus-driven tumor growth

CCR1 is differentially expressed across ovarian cancer subtypes

Phase II dose of cancer vaccine IMU-131 identified in HER2/neu-overexpressing stomach cancer trial

Phase II study of AXS-05 for smoking cessation meets prespecified primary endpoint

Alnylam initiates global phase III pediatric ILLUMINATE-B study

Clinical program update on ADVM-022 gene therapy

Synapse formation important for ketamine durability

Preclinical characterization of PF-06882961

S100B SNPs and haplotypes as markers of acute and chronic pain in sickle cell disease

RTI-1092663 improves metabolic syndrome in mice

Shenyang Pharmaceutical University patents neuraminidase inhibitors

Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS

FDA gives clearance to initiate phase II/III study of ARO-AAT for AATD liver disease

Diamyd Medical presents 30-month results from phase IIa EDCR study

MediciNova moves forward with a phase III study of MN-166 in ALS

CStone Pharmaceuticals announces dosing of first patient in phase III GEMSTONE-303 study

Positive interim results presented from phase I study of CERC-301

Positive 12-month data presented from phase II study of Clascoterone

Interim results presented from phase II study of chikungunya virus vaccine candidate

Cortexyme launches phase II/III study of COR-388 in subjects with Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...